Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01875848 · ClinicalTrials.gov registry record · Phase 4
Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain
A Phase 4 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT01875848: Clinical Trial Phase 4 study, sponsored by VA Office of Research and Development.
NCT01875848 is a Phase 4 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01875848, a Phase 4 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study compares buprenorphine/naloxone to opioid dose escalation among patients with poorly controlled non-cancer pain on 30-100 mg daily morphine equivalent opioid dose.
Interventions
- DRUG buprenorphine/naloxone
- DRUG opioid dose escalation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01875848
The ClinicalTrials.gov registry entry for NCT01875848 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which buprenorphine/naloxone is the first listed.
NCT01875848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01875848 about?
NCT01875848 is a clinical study titled "Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain". This study compares buprenorphine/naloxone to opioid dose escalation among patients with poorly controlled non-cancer pain on 30-100 mg daily morphine equivalent opioid dose.
What is the current status of trial NCT01875848?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2013-12. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01875848?
The interventions under investigation include: buprenorphine/naloxone (DRUG), opioid dose escalation (DRUG).
Who is sponsoring clinical trial NCT01875848?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.